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ABSTRACT
Severe strongyloidiasis, caused by Strongyloides stercoralis, is a preventable life-threatening disease that
can occur in any corticosteroid-treated patient who has travelled to a country with infested soil, even if
the contact occurred up to 30 years previously. This diagnosis should be considered in corticosteroid-
treated patients who experience either unusual gastrointestinal or pulmonary symptoms, or who suffer
from unexplained sepsis caused by Gram-negative bacilli. Peripheral eosinophilia is not observed
systematically and, even if present, is moderate in most cases. Ivermectine is the best prophylactic and
therapeutic option, and thiabendazole should no longer be used. However, guidelines for the prevention
and management of S. stercoralis infection in such patients have not yet been established.
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Strongyloides stercoralis is an ubiquitous soil-trans-
mitted intestinal nematode that is endemic in
many areas throughout both tropical (sub-Saha-
ran Africa, South-east Asia, Latin America) and
temperate regions (south-eastern USA, some
European countries) [1,2]. The free-living rhabdi-
tiform larva that is present in humid soils
develops into a ﬁlariform larva when the
microenvironment changes to unfavourable cir-
cumstances. Following contact between human
skin and contaminated soil, the ﬁlariform larva
penetrates the skin and migrates through the
lungs before settling in the intestine. The parasite
may then cause a long-lived autoinfection in the
host [2], leading to a chronic disease that can last
for several decades. In immunocompetent hosts,
infection by S. stercoralis may induce minor
cutaneous, pulmonary or gastrointestinal symp-
toms, but is asymptomatic in most cases. How-
ever, under some conditions, the autoinfection
may result in the dissemination of larvae into
extra-intestinal tissues and organs, leading to
hyperinfection syndrome (massive invasion by
ﬁlariform larvae in the bowel and often in the
lungs) or the disseminated form (presence of
worms in extra-intestinal and extra-pulmonary
sites) of the disease [2]. However, these two
patterns of severe infection by S. stercoralis are not
always distinguishable during a patient’s lifetime,
and may represent distinct progression stages of
the same disease. Thus, as suggested previously
[2,3], these two forms of the disease may be
grouped together as severe strongyloidiasis.
The link between corticosteroid therapy and
strongyloidiasis has been reported widely. While
corticosteroid therapy is associated with a two- to
three-fold increase in the risk for being infected by
S. stercoralis [4,5], immunodepression induced by
corticosteroids is a condition that triggers severe
forms of the disease in asymptomatic patients [2].
However, little is known concerning the mecha-
nisms by which corticosteroids are involved in
determining susceptibility to severe S. stercoralis
infection. It has been hypothesised that cortico-
steroids increase susceptibility to parasitic infec-
tion through their suppressive effects on some of
the major mediators of the immune response to S.
stercoralis larvae, such as eosinophils [6,7]. It has
also been suggested that corticosteroids may have
a direct effect on the parasites by precipitating
dissemination of S. stercoralis [8].
Severe strongyloidiasis has no pathognomonic
clinical picture and is therefore difﬁcult to diag-
nose, particularly in corticosteroid-treated pa-
tients. Gastrointestinal and pulmonary symptoms
are common, but not speciﬁc (e.g., anorexia,
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nausea, diarrhoea, abdominal bloating or discom-
fort, cough, dyspnoea, wheezing, acute pulmon-
ary insufﬁciency). Fever, usually low grade, or
even totally masked by corticosteroids, does not
cause great concern. Skin involvement, character-
ised by a migratory, serpiginous, urticarial rash
(termed larva currens) is more suggestive, but is
observed rarely. Furthermore, symptoms associ-
ated with severe strongyloidiasis may mimic a
relapse of the disease that was being treated by
corticosteroids (e.g., asthma, chronic obstructive
pulmonary disease, Crohn’s disease), resulting in
an inappropriate increase in the dose of cortico-
steroids and a delay in the initiation of effective
therapy. Peripheral blood eosinophilia is low in
most corticosteroid-treated patients with severe
strongyloidiasis (68% of the 151 cases described
in the medical literature; unpublished personal
data), probably because of the eosinophil-low-
ering action of corticosteroids.
Severe strongyloidiasis has been associated
with a high incidence of bacterial or yeast infec-
tions [9,10], and sepsis involving Gram-negative
bacilli is a common symptom that reveals the
underlying occulted parasitic infection. The pos-
tulated mechanism for sepsis in such cases is
transmission of enteric bacteria through the bowel
wall by invading ﬁlariform larvae [10,11]. How-
ever, parasitologists have proposed two other
mechanisms to explain bacteraemia: (i) adherence
of bacteria to the external surfaces of the larvae as
they enter the bloodstream; or (ii) excretion of
bacteria from the alimentary canals of larvae
when they travel in the bloodstream [12]. There-
fore, sepsis in corticosteroid-treated patients may
reﬂect an underlying infection with S. stercoralis,
particularly if the patient has experienced unspe-
ciﬁc gastrointestinal or pulmonary symptoms.
Once the diagnosis of severe strongyloidiasis is
suspected, it should be conﬁrmed by obtaining
evidence of S. stercoralis involvement. Detection of
the parasite may be achieved in stool samples by
various techniques, including a faecal smear in
saline–Lugol, iodine stain, Baermann concentra-
tion, formalin-ethyl acetate concentration, Harada-
Mori ﬁlter-paper culture, or nutrient agar plate
culture [2]. In immunocompetent patients, it has
been shown that the highest sensitivity (96%) for
the detection of larvae is achieved by agar plate
culture [13], which is at least four-fold more
efﬁcient than the direct smear procedure [14].
However, this technique is time-consuming,
requiring 2–3 days, which may be too long a
period once the diagnosis is suspected in an
immunocompromised host. In cases of severe
strongyloidiasis, the high number of worms
involved means that larvae may also be identiﬁed
in duodenal aspirate, sputum or bronchoalveolar
lavage ﬂuid. The parasite should be sought
systematically when bronchoscopy or gastrosco-
py is performed in a corticosteroid-treated patient
experiencing gastrointestinal or pulmonary
symptoms. Occasionally, S. stercoralis has also
been identiﬁed from urine, pleural, peritoneal or
cerebrospinal ﬂuid, or in biopsy samples (intesti-
nal mucosa or skin) in such patients.
An ELISA test (Strongyloides antibody) for
detecting serum IgG against a crude extract of
the ﬁlariform larvae of S. stercoralis is available
only in specialised centres. In immunocompetent
hosts, the sensitivity of this test is 88–95%, the
speciﬁcity is 29–99%, the positive predictive
value is 30–97%, and the negative predictive
value is > 90% [15,16]. There are no similar data
available for immunocompromised hosts. More-
over, because the serological results may remain
positive for months to years after a successfully
treated infection, and may even cross-react
with other helminth infestations, its role in the
diagnosis of severe strongyloidiasis remains
secondary.
There are no established guidelines and few
data in the literature concerning the prevention
and management of S. stercoralis infection in
immunocompromised patients. Portugal et al.
[17] tested the efﬁcacy of thiabendazole for
strongyloidiasis prophylaxis in 103 patients with
haematological disease or benign conditions who
were receiving corticosteroids. The drug was not
superior to a placebo (the strongyloidiasis inci-
dence rate was 2% vs. 7%, respectively; p 0.36),
but the statistical power of the study was lower
than projected. Moreover, experience in patients
with AIDS has suggested that ivermectin (200
lg ⁄ kg ⁄day on days 1, 2, 15 and 16) may be the
drug of choice for treating strongyloidiasis in
immunocompromised patients [18]. Thus, iver-
mectin is now the preferred choice for the pre-
vention and management of uncomplicated
strongyloidiasis. Nevertheless, these data provide
no evidence concerning the drug of choice and the
optimal treatment protocol for cases of severe
strongyloidiasis. However, because mortality
rates caused by severe strongyloidiasis can reach
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80% [10], and because most cases can be preven-
ted by early detection and treatment of asympto-
matic chronic infection, a systematic preventive
therapy should be prescribed for all patients
scheduled to receive corticosteroids who have
travelled in endemic areas.
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